The investment decisions made by the biggest players in core disease areas drive market trends—so it’s crucial to understand where the big money is going and why. And as advancements in technology as well as business forces are inspiring fresh thinking in R&D, data, systems and commercial models, itis critical to be on top of the bigger picture.
As CDx and BM move outside of their heartland of oncology into conditions such as rheumatoid arthritis and depression, what do payers want and expect from pharma and CDx developers to really drive wider use of CDx? In Companion Diagnostics and Biomarkers: Payer Perspectives, experienced US and European payers assess the current CDx and BM landscape and identify the issues, challenges and opportunities that industry must address.
Payers tackle key questions:
- What are the key drivers for CDx and BM adoption and how will the market evolve over the next five years?
- What is the value proposition of CDx from a payer perspective and what are the key drivers for adoption?
- What assessment criteria do payers apply to determine the coverage of CDx and BM tests and for negotiating pricing and reimbursement?
- Is funding an issue and if so what do CDx manufacturers and pharma need to provide in order to ensure coverage?
- As new more complex tests emerge will current funding models be flexible enough to enable reimbursement of CDx and BMs, and if not, what needs to be done?
- What should test manufacturers do to drive future uptake of CDx and BM-based tests?